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The respiratory disease field is changing because of
recent advances in our understanding of the airway
microbiome. Central to this is dysbiosis, an imbalance
of microbial communities that can lead to and flag
inflammation in the airways. The increasing momentum
of research in this area holds promise for novel
treatment strategies.Topographical and ecological perspective of the
The airway microbiome is changing the
respiratory disease field
In the past decade, a multiplicity of evidence has
emerged in support of the central role of the human
microbiome in the etio-pathogenesis of a wide variety of
diseases. Work in this area has been aided by the
increasing application of culture-independent microbial
detection tools, such as high-throughput sequencing and
metagenomics. Owing to the relative accessibility of the
upper airway, previous attention has focused on
sampling microorganisms from this region as represen-
tative of the airway microbiota. Recently, however,
characterization of the lower-airway microbiota within
the context of respiratory health and disease has
prompted a shift away from the age-long credo of
sterility of the lower airways, towards an overall consid-
eration of the vital role of host-microbiota interactions
in respiratory health.
Concurrently, interest on the role of non-bacterial
members of the microbiota — viruses and fungi — is
beginning to emerge. Notably, a complex mixture of
bacterial and fungal communities has been identified in
the airways of patients with cystic fibrosis. In addition,
human tissue surfaces, including the lungs, harbor
diverse viral populations [1]. Numerous gaps remain in
our understanding of how ecological balance is achieved* Correspondence: benjamin.marsland@chuv.ch
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terial communities. As is now well established within
the context of intestinal diseases, the local microbiota is
a dominant player in maintaining a healthy homeostasis
or in driving the development of disease. In the respira-
tory field, this emerging paradigm could have a signifi-
cant impact on the goal of moving from symptomatic
treatment to cures.airway microbiome
The human respiratory tract is not homogenous but is
comprised of microhabitats that are distinguished by
different constitutive physico-chemical properties, such
as pH, temperature, oxygen concentration, mucus pro-
duction and nutrient availability, all of which could
potentially shape the composition of the airway micro-
biota [2]. The presence of different microbial species in
the airways may also be an indication of physiochemical
property gradients within the airway microhabitats,
allowing different regions of the airways to meet the sur-
vival needs of different microbial species. Other factors,
such as inspiratory influx of nasopharyngeal and/or oral
microbiota, or efficiency of physical elimination by
coughing and micro-aspiration of gastro-esophageal
contents, may also contribute to the topographical het-
erogeneity of the airway microbiota.
The currently proposed concept of a ‘healthy’ airway
microbiota in humans, consisting of several putative air-
way pathogens, contradicts established models of infec-
tion in sterile tissues. For instance, the six dominant
genera in the upper airway microbiota in children have
been shown to be Haemophilus, Streptococcus, Coryne-
bacterium, Staphylococcus, Moraxella, and Alloiococcus
[3], members of which are commonly implicated in re-
spiratory tract infections. Similarly, studies in the bron-
choalveolar lavage fluid of healthy adults have shown a
high frequency of potential ‘pathogens’, including
Pseudomonas, Streptococcus, Prevotella, Fusobacterium,
Haemophilus, Veillonella, and Porphyromonas [4]. InAccess article distributed under the terms of the Creative Commons Attribution
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with Streptococcus pneumoniae, which has been shown
to predate invasive pneumococcal disease in children, is
characterized by a dysbiotic precursory outgrowth of
S. pneumoniae within the nasopharyngeal microbiota [5].
Highlighting the role of the microbiota in shaping air-
way immunity, Teo and colleagues [3] recently examined
the microbiota from nasopharyngeal aspirates collected
within the first year of life from a cohort of 234 children,
using 16S rRNA gene sequencing. They observed that
dynamic transitions occurred within the nasopharyngeal
microbiota, with early colonizers, Staphylococcus and
Corynebacterium, replaced at one year by Alloicoccus
and Moraxella. Importantly, these authors found signifi-
cant associations between nasopharyngeal colonization
by Haemophilus, Streptococcus and Moraxella and
increased risks of virus-associated acute respiratory ill-
nesses [3]. The subsequent risk of early childhood
asthma was elevated as a consequence of microbiota-
associated susceptibility to acute viral illnesses, especially
asymptomatic streptococcal colonization in the first year
of life [3]. There are two key lessons that can be drawn
from this study. First, the composition of microbial com-
munities within the nasopharynx in early life can deter-
mine susceptibility to viral infections of the lower
airways. Second, and perhaps more importantly, early
life changes in host–microbiota interactions may lead to
long-term predisposition to airway inflammation. There-
fore, within the context of airway infection, dynamic
inter-species interactions that exist within poly-
microbial niches in the airway microbiota may dictate
the pathogenic potential of any single bacterial species,
tipping the balance towards infection and chronic airway
inflammation.
Microbial dysbiosis in airway disease
Previous studies have suggested a link between microbial
dysbiosis, defined as a perturbation in the structure of
complex microbial communities [6], and the pathogen-
esis of chronic lung diseases, including chronic obstruct-
ive pulmonary disease [4] and allergic asthma [7].
Within the context of asthma, it is currently unclear
whether dysbiosis represents an underlying susceptibility
to airway colonization by certain bacteria or if the
microbiota directly drives the aberrant inflammatory im-
mune responses that characterize asthma. From an eco-
logical standpoint, however, asthma-associated dysbiosis
could result from a breakdown in balanced inter-species
interactions within the lung microbiota that selects for
outgrowths of dominant members, which could explain
the association between antibiotic use in early life and
subsequent risk of asthma [8]. A similar scenario of
dysregulated ecological balance within microbial niches
may underlie aberrant inflammation and chronicityassociated with other chronic lung disorders, such as
cystic fibrosis and idiopathic pulmonary fibrosis.
Low diversity of the gut microbiota in early infancy
has been shown to be an important risk factor for the
development of allergy. Furthermore, epidemiological
evidence suggests an association between growing up in
a farm environment, with early life exposure to barn-
derived microbes and unpasteurized milk consumption,
and decreased risk of developing allergy later in life [9].
Evidence from experiments in mouse models also
alludes to the relevance of early life exposure in the
education of developing host immune cells to allow
tolerance of aero-allergens [10]. The protective effect of
early life microbial exposure in the setting of allergic
airway inflammation fits with the current paradigm of
critical developmental windows in early life, when
dysregulated host–microbiota interactions result in life-
long sequelae.
Current challenges and future directions
A substantial body of evidence now supports the
concept that dysregulation of host–microbiota crosstalk
at body surfaces may underlie chronic inflammatory dis-
orders. From a clinical perspective, there is growing
interest in the prospects of translating the results of
airway microbiome analyses into practical patient-
management tools for lung diseases; but in order to ac-
celerate translational prospects of airway microbiome
research, several challenges will need to be addressed.
First, a harmonization of methodologies for airway sam-
ple collection, processing and analysis is required to pro-
vide comparable datasets. In addition, more work is
needed to elucidate the broader interactions between
bacterial, viral and fungal components of the microbiota
and how they impact airway disease pathogenesis.
Finally, a functional characterization of the airway
microbiota using animal models and proteomic, tran-
scriptomic and metabolomic approaches should provide
crucial insights into how differential characteristics of
the airway microbiota impact respiratory health. Specif-
ically, these tools may provide insights into the predom-
inant transcriptional and metabolic pathways, small
molecules and metabolites within the microbiota that
mediate host–microbiota and microbe–microbe interac-
tions. Microbiota-derived metabolic pathways and me-
tabolites could serve as future therapeutic targets in
airway diseases.
A microbiota profile may serve as a future diagnostic
or prognostic marker in airway inflammation. Similarly,
changes in the microbiota could become indicators for
monitoring airway disease progression and could guide
therapeutic interventions. Approaches towards deliberate
manipulation of the airway microbiota opens exciting pos-
sibilities for non-antibiotic-based treatment modalities in
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engineering the microbiota, by use of metabolites or pro-
biotics during critical developmental windows in early life,
may serve as an important prophylactic intervention to
prevent chronic airway inflammation.
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